| Followers | 14 |
| Posts | 343 |
| Boards Moderated | 0 |
| Alias Born | 10/18/2023 |
Friday, November 14, 2025 7:16:39 PM
Also for those interested: Here are some revised back of the number estimates should another Alzheimer's trial be required.
Assumptions: Trial cost: $300 million over 36-48 months, or around $7.5mm per month. Anavex will dilute 90mm shares @ $2.25/share if it hasn't already, so that $200 million + the $100 million in the bank should be able to cover the cost of the Alzheimer's trial.
For the EU: 3mm people; $6500/year (I read this is the most that is feasible for the majority of countries); 185mm shares outstanding; 18% net income; 20x P/E
So: 3mm x $6500 x .18 / 185mm x 20 = $380/share
Or, assume a 3x sales price: It's around $315/share.
The point is there is still value to be unlocked here even with massive dilution and lost opportunity cost. Whether someone has the patience to wait and see how this plays out, remains to be seen, but if I thought I had a lotto ticket and they told me that the drawing got pushed back from January '26 to January '29, and if I didn't need the money now, I probably wouldn't sell it for $3. I'd put it in the safe and forget about it for a while.
Best of luck. I'll be lurking from time to time.
Assumptions: Trial cost: $300 million over 36-48 months, or around $7.5mm per month. Anavex will dilute 90mm shares @ $2.25/share if it hasn't already, so that $200 million + the $100 million in the bank should be able to cover the cost of the Alzheimer's trial.
For the EU: 3mm people; $6500/year (I read this is the most that is feasible for the majority of countries); 185mm shares outstanding; 18% net income; 20x P/E
So: 3mm x $6500 x .18 / 185mm x 20 = $380/share
Or, assume a 3x sales price: It's around $315/share.
The point is there is still value to be unlocked here even with massive dilution and lost opportunity cost. Whether someone has the patience to wait and see how this plays out, remains to be seen, but if I thought I had a lotto ticket and they told me that the drawing got pushed back from January '26 to January '29, and if I didn't need the money now, I probably wouldn't sell it for $3. I'd put it in the safe and forget about it for a while.
Best of luck. I'll be lurking from time to time.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
